The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...

This came after Hetero Labs presented the BE study protocol, vide no. AZBE112405, Version No. 01, Dated 15.11.2024 and the ...

The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market impact. Read more on ALT stock here.

A mother revealed that she shed 165 lbs (approx. 75 kg) after using Ozempic. Amy Kane, from Chicago, shared her remarkable ...

Semaglutide is a glucagon-like peptide-1 receptor ... once weekly Number of clicks 0.25 and 0.5 mg (2 mg/3 mL) 0.5 mg • 0.4 mg Most clinical trials of Ozempic compared once-weekly doses of ...

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

It’s also slashing the cost of 2 mg and 5 mg vials by $50 a month ... In late February, the FDA delisted semaglutide, sold under the brand names Ozempic and Wegovy. Compounding pharmacies ...

New research has identified cannabis-derived terpenes—compounds that give plants their distinctive aroma—as effective ...

On the positive side, Novo Nordisk A/S (NYSE:NVO) made headlines last month after it revealed encouraging results from a trial for Semaglutide 7.2 mg, demonstrating superior weight loss compared ...